Supplementary Table 1. Baseline characteristics of the participants

Characteristic	All participants (n=3,061)	Participants with TBIL ≤17 μmol/L (n=2,219)	Participants with TBIL >17 μmol/L (n=842)	*P*
Age (yr)	61.2±6.7	61.1±6.7	61.5±6.6	0.060
Male sex	1,424 (46.5)	858 (38.7)	566 (67.2)	<0.001
Current smoking	627 (20.5)	437 (19.7)	190 (22.6)	0.079
Current drinking	573 (18.7)	328 (14.8)	245 (29.1)	<0.001
BMI (kg/m^2)	23.8±3.0	23.8±3.1	23.8±3.0	0.527
SBP (mm Hg)	129.3±16.3	129.1±16.7	129.6±15.5	0.344
DBP (mm Hg)	75.2±9.0	74.7±9.0	76.5±9.0	<0.001
FBG (mmol/L)	6.0±1.6	5.9±1.5	6.0±1.8	0.440
HbA1c (%)	5.9±0.9	6.0±0.9	5.9±1.0	<0.001
TC (mg/dL)	201.9 (178.0–227.8)	203.5 (181.1–229.0)	198.1 (170.7–223.2)	<0.001
TG (mg/dL)	129.2 (92.0–189.4)	130.1 (93.8–192.0)	126.5 (87.6–185.0)	0.010
HDL-C (mg/dL)	51.0 (43.6–60.6)	51.0 (43.6–59.8)	51.7 (44.0–61.8)	0.159
LDL-C (mg/dL)	105.8 (86.9–126.6)	107.3 (88.8–128.2)	100.8 (80.7–122.4)	<0.001
TBIL (μmol/L)	13.6 (10.7–17.7)	12.0 (9.9–14.2)	20.9 (18.8–25.2)	<0.001
DBIL (μmol/L)	4.9 (4.0–6.2)	4.4 (3.7–5.1)	7.3 (6.5–8.5)	<0.001
IBIL (μmol/L)	8.6 (6.7–11.4)	7.6 (6.0–9.0)	13.8 (12.3–16.8)	<0.001
Hypertension	1,317 (43.0)	943 (42.5)	374 (44.4)	0.338
Diabetes	661 (21.6)	466 (21.0)	195 (23.2)	0.195
Dyslipidemia	1,277 (41.7)	954 (43.0)	323 (38.4)	0.020
Concomitant medication				
Antihypertensive	820 (26.8)	591 (26.6)	229 (27.2)	0.753
Lipid-lowing	120 (3.9)	79 (3.6)	41 (4.9)	0.096
Antidiabetic	273 (8.9)	206 (9.3)	67 (8.0)	0.250
Antiplatelet	80 (2.6)	52 (2.3)	28 (3.3)	0.128
Anticoagulant	4 (0.1)	1 (0.05)	3 (0.4)	0.066

Values are presented as mean±standard deviation, n (%), or median (interquartile range).
TBIL, total bilirubin; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; DBIL, direct bilirubin; IBIL, indirect bilirubin.